Equities

Probi AB

Probi AB

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (SEK)351.00
  • Today's Change0.00 / 0.00%
  • Shares traded75.11k
  • 1 Year change+72.91%
  • Beta0.5133
Data delayed at least 15 minutes, as of Nov 21 2024 17:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of SEK
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments330324251
Total Receivables, Net8496126
Total Inventory11711694
Prepaid expenses4.553.982.99
Other current assets, total5.84----
Total current assets540540474
Property, plant & equipment, net195212167
Goodwill, net341354307
Intangibles, net340382380
Long term investments7381101
Note receivable - long term------
Other long term assets003.27
Total assets1,4901,5701,432
LIABILITIES
Accounts payable343446
Accrued expenses243019
Notes payable/short-term debt000
Current portion long-term debt/capital leases161715
Other current liabilities, total4.095.176.11
Total current liabilities788686
Total long term debt385463
Total debt547078
Deferred income tax01413
Minority interest------
Other liabilities, total5.275.484.75
Total liabilities121159167
SHAREHOLDERS EQUITY
Common stock585858
Additional paid-in capital600600600
Retained earnings (accumulated deficit)613611585
Treasury stock - common------
Unrealized gain (loss)(36)----
Other equity, total13314122
Total equity1,3691,4111,266
Total liabilities & shareholders' equity1,4901,5701,432
Total common shares outstanding111111
Treasury shares - common primary issue000.25
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.